ARAF is altered in 3.03% of pancreatic ductal adenocarcinoma patients [2].

ARAF is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATM is altered in 5.71% of pancreatic ductal adenocarcinoma patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

ATR is altered in 6.06% of pancreatic ductal adenocarcinoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

BARD1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain BARD1 status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].

BRAF is altered in 2.78% of pancreatic ductal adenocarcinoma patients [2].

BRAF is an inclusion eligibility criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRAF status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

BRCA1 is altered in 2.94% of pancreatic ductal adenocarcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA1 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [3].

BRCA2 is altered in 2.94% of pancreatic ductal adenocarcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA2 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [3].

BRIP1 is altered in 3.12% of pancreatic ductal adenocarcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRIP1 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDK12 is altered in 3.03% of pancreatic ductal adenocarcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDKN2A is altered in 48.57% of pancreatic ductal adenocarcinoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK1 is altered in 3.03% of pancreatic ductal adenocarcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHEK1 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHEK2 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CTNNB1 is altered in 2.78% of pancreatic ductal adenocarcinoma patients [2].

CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCA is altered in 3.03% of pancreatic ductal adenocarcinoma patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCA status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCB status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FANCC is altered in 3.12% of pancreatic ductal adenocarcinoma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCC status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCD2 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCE status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCF status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCG status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCI status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCL status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCM status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

HRAS is an inclusion eligibility criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain HRAS status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [3].

KRAS is altered in 80.56% of pancreatic ductal adenocarcinoma patients [2].

KRAS is an inclusion eligibility criterion in 7 clinical trials for pancreatic ductal adenocarcinoma, of which 5 are open and 2 are closed. Of the trials that contain KRAS status and pancreatic ductal adenocarcinoma as inclusion criteria, 5 are phase 1 (4 open) and 2 are phase 1/phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MCPH1 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

MRE11A is altered in 3.03% of pancreatic ductal adenocarcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MRE11A status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

MTAP is altered in 4.55% of pancreatic ductal adenocarcinoma patients [2].

MTAP is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NBN status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

NRAS is an inclusion eligibility criterion in 4 clinical trials for pancreatic ductal adenocarcinoma, of which 2 are open and 2 are closed. Of the trials that contain NRAS status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].

PTEN is altered in 8.57% of pancreatic ductal adenocarcinoma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTEN status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD50 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51B status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RAD51C is an inclusion eligibility criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51C status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51D status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].

RAD54L is altered in 4.35% of pancreatic ductal adenocarcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD54L status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SLX4 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

TP53 is altered in 74.29% of pancreatic ductal adenocarcinoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].